Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 15/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4062423 | 1.00 | HTR1A (0.46) | HTR1ADRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL29624058 | 1.00 | HTR1A (0.46) | HTR1ADRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL9676250 | 0.87 | HTR1A (0.47) | HTR1ADRD2DRD3 | |
| Tibo SCHEMBL8013680 | 0.83 | GRIN2D (0.31) | HTR1ADRD2 | |
| Tibo SCHEMBL1077005 | 0.83 | GRIN2D (0.31) | HTR1ADRD2 | |
| Tibo SCHEMBL29623959 | 0.83 | GRIN2D (0.31) | HTR1ADRD2 | |
| SCHEMBL9531050 | 0.81 | HTR1A (0.55) | HTR1ADRD2DRD3 | |
| SCHEMBL7905347 | 0.81 | HTR1A (0.32) | HTR1ADRD2 | |
| SCHEMBL7908075 | 0.81 | HTR1A (0.48) | HTR1ADRD2DRD3 | |
| SCHEMBL7903407 | 0.81 | HTR1A (0.31) | HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| EP-0513917-B1 | Antiviral combinations containing nucleoside analogs | GLAXO GROUP LTD (GB) | 1995-12-20 | — | — | EP | claimed |
| EP-0666744-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1995-08-16 | — | — | EP | claimed |
| WO-1994009781-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1994-05-11 | — | — | WO | claimed |
| EP-0384522-B1 | Antiviral tetrahydroimidazo[1,4]benzodiazepin-2-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-01-13 | — | — | EP | claimed |
| WO-1992020344-A1 | ANTIVIRAL COMBINATIONS CONTAINING NUCLEOSIDE ANALOGS | GLAXO GROUP LIMITED (GB) | 1992-11-26 | — | — | WO | claimed |
| EP-0513917-A1 | Antiviral combinations containing nucleoside analogs | GLAXO GROUP LIMITED (GB) | 1992-11-19 | — | — | EP | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4342543-B1 | TERT-BUTYL 2-(4-PHENYL-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2000003998-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-01-27 | — | — | WO | disclosed |
| EP-0970078-A1 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998041522-A9 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | — | 1999-03-04 | — | — | WO | disclosed |
| WO-1998041522-A1 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 1998-09-24 | — | — | WO | disclosed |
| US-5811460-A | Water soluble fullerenes with antiviral activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0666744-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994009781-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | HTR1A 3728/4885DRD2 3022/4885SIGMAR1 3184/4885 |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | HTR1A 3585/4885DRD2 4166/4885SIGMAR1 2933/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | HTR1A 4319/4885DRD2 4637/4885SIGMAR1 3403/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | HTR1A 3846/4885DRD2 4361/4885SIGMAR1 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.